Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03639779
Other study ID # BIO-18-14095
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date November 2, 2018
Est. completion date December 31, 2019

Study information

Verified date June 2021
Source University of Central Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of our research is to compare the effectiveness of 125mg/50ml sodium thiosulfate (STS) solution to normal saline (0.9% sodium chloride) when injected intralesionally for the treatment of calcinosis cutis. Our specific aim is to assess the response of dystrophic and idiopathic calcinosis cutis to the injections of sodium thiosulfate in our patients.


Description:

Our specific aim is to assess the response of dystrophic and idiopathic calcinosis cutis to the injections of sodium thiosulfate in our patients.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female adult 18 years of age or older - Must have health insurance will be eligible to participate - Must have a current diagnosis of dystrophic or idiopathic calcinosis cutis - Subjects must have at least 2 lesions of at least 2mm in size Exclusion Criteria: - Unable to read and speak English - Allergy to any component of the sodium thiosulfate solution - Adults unable to consent - Individuals who are not yet adults (infants, children, teenagers) - Pregnant women - Women who are breastfeeding - Prisoners

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sodium Thiosulfate
A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
Other:
Saline Solution
A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.

Locations

Country Name City State
United States UCF Health Lake Nona Office Orlando Florida

Sponsors (1)

Lead Sponsor Collaborator
University of Central Florida

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lesion Size The lesion size is measured in square centimeters. 3 months
Primary Physician Global Assessment (PGA) The PGA will be done by the physician to assess appearance and changes in the lesion. The lesion will be assigned a score from 0 (clear) to 4 (severe). 3 months
Primary Visual Analog Scale (VAS) for Pain The VAS for pain is used to assess the pain associated with the lesion. The pain will be recorded as a number from 1 (no pain) to 10 (severe pain). 3 months
See also
  Status Clinical Trial Phase
Withdrawn NCT01918904 - A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis Phase 2
Not yet recruiting NCT05870852 - Effectiveness of ESWT and PNF in Scleroderma With Calcinosis N/A
Not yet recruiting NCT03972566 - Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon